prmt5 inhibitor tng456
Generic: PRMT5 Inhibitor TNG456
prmt5 inhibitor tng456: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Tango Therapeutics, Inc. (TNGX) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Frequently asked questions
Who is developing prmt5 inhibitor tng456?
prmt5 inhibitor tng456 is being developed by Tango Therapeutics, Inc..
How many clinical trials involve prmt5 inhibitor tng456?
BioSniper tracks 1 clinical trial involving prmt5 inhibitor tng456.
Get deeper analysis on prmt5 inhibitor tng456
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis